A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Inclusion Criteria:

• Persistent or recurrent EOC that meets the following criteria: Histologicallyconfirmed non-high-grade serous, non-high-grade endometrioid epithelial ovarian,fallopian tube, or primary peritoneal cancer, including but not limited to low-gradeserous ovarian carcinoma, clear cell carcinoma, mucinous carcinoma, carcinosarcoma,undifferentiated carcinoma, seromucinous carcinoma, malignant Brenner tumors, Grades 1 or 2 endometrioid carcinoma, mesonephric-like adenocarcinoma and small cellcarcinoma of the ovary, hypercalcemic type (SCCOHT). Disease that is not amenable tocurative surgery

• Measurable disease (at least one target lesion) according to RECIST v1.1

• Previous treatment with one to four lines of therapy, at least one of which wasplatinum-based. Hormonal therapy does not count as a line of therapy.

• Platinum-resistant disease, defined as disease progression during or within 6 monthsof last platinum therapy, with the following exception: Participants with primaryplatinum-refractory disease are excluded.

• Submission of a representative tumor specimen that is suitable for next-generationsequencing (NGS) testing and estrogen receptor immunohistochemistry (ER IHC) todetermine treatment arm assignment and for central pathology review.

• Submission of the local pathology report and, if available, any associated stainedslides that supported the local diagnosis of the histology (to be used for centralpathology review)

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

• Adequate hematologic and end-organ function

• For women of childbearing potential: agreement to remain abstinent or usecontraception, and agreement to refrain from donating eggs (if applicable)

• In addition to the general inclusion criteria above, participants must meet all ofthe arm-specific inclusion criteria for the respective arm

General Exclusion Criteria:

• Pregnant or breastfeeding, or intending to become pregnant or breastfeed during thestudy

• Primary platinum-refractory disease, defined as progression during or within 4 weeksafter the last dose of the first-line platinum treatment

• Histologic diagnosis of high-grade serous or high-grade endometrioid ovarian,fallopian tube, or primary peritoneal cancer

• Current diagnosis of solely borderline epithelial ovarian tumor

• Current diagnosis of non-epithelial ovarian tumors

• Current diagnosis of synchronous primary endometrial cancer

• Prior history of primary endometrial cancer, with the following exception: a priordiagnosis of primary endometrial cancer is permitted if it meets all of thefollowing conditions: Stage IA, no lymphovascular invasion, International Federationof Gynecology and Obstetrics Grade 1 or 2, not a high-grade subtype.

• Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrentdrainage procedures

• Symptomatic, untreated, or actively progressing CNS metastases

• Severe infection within 4 weeks prior to initiation of study treatment

• Treatment with chemotherapy, radiotherapy, antibody therapy or other immunotherapy,gene therapy, vaccine therapy, or investigational therapy within 28 days prior toinitiation of study treatment

• Treatment with hormonal therapy within 14 days prior to initiation of studytreatment

• In addition to the general exclusion criteria above, participants can not meet anyof the arm-specific exclusion criteria for the respective arm